- 873studies on this subject, of 27,380 in the library
- 823peer-reviewed
- 1964–2026years published
- 40median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study. For a plain-English guide to this subject, see Treatments.
The 20 highest-scoring studies
- Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis
- Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis
- TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease
- The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
- CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures
- Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
- Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review
- Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial
- Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men
- Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial
- Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
- Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies
- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease
- Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis
- Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
- Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial
- Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
- Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis
- Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study
- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study
See all 873 studies in Drug development, with filters →
Newest additions on this subject
- The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration
- Effect of Metformin on tau pathology and proteostasis in cellular and a Drosophila model of Tauopathy
- Beyond Glycemic Control: The Pleiotropic Role of GLP-1RAs and Melatonin in Combating Neuroinflammation and Mitochondrial Dysfunction
- Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications
- Predictors of Antiamyloid Medication Utilization and Adherence Among People With Alzheimer Disease and Mild Cognitive Impairment
- In Vivo Transcriptomics-Based Framework for Systematic Indication Expansion
- Progranulin deficiency promotes neuroinflammation through cathepsin B-mediated activation of the NLRP3 inflammasome
- Patterns of GLP-1 Receptor Agonist Initiation Compared With Other Glucose-Lowering and Anti-Obesity Therapies Among Older Adults
- Repetitive RNA Is Present in Prion-Infected Mouse Brains
- Predicting Rates of Cognitive Decline in Older Adults with Brain- and Cardiac-Imputed Transcripts
All 873 studies in Drug development, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 823 |
| Preprint — not yet peer-reviewed | 47 |
| Retracted — do not rely on it | 3 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| low | 742 |
| high | 83 |
| moderate | 47 |
| not rated | 1 |
Most frequent journals
| Journal | Studies |
|---|---|
| Journal of Alzheimer's disease : JAD | 21 |
| International journal of molecular sciences | 15 |
| Neurology | 14 |
| Research Square | 14 |
| bioRxiv | 14 |
| Acta neuropathologica | 13 |
| Alzheimer's research & therapy | 13 |
| The Journal of neuroscience : the official journal of the Society for Neuroscience | 13 |
| Neuropharmacology | 12 |
| Proceedings of the National Academy of Sciences of the United States of America | 12 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 58 | |
| 2025 | 60 | |
| 2024 | 77 | |
| 2023 | 49 | |
| 2022 | 75 | |
| 2021 | 57 | |
| 2020 | 47 | |
| 2019 | 49 | |
| 2018 | 39 | |
| 2017 | 36 | |
| 2016 | 22 | |
| 2015 | 35 | |
| 2014 | 26 | |
| 2013 | 27 | |
| 2012 | 24 | |
| 2011 | 18 | |
| 2010 | 14 | |
| 2009 | 22 | |
| 2008 | 13 | |
| 2007 | 10 | |
| 2006 | 8 | |
| 2005 | 8 | |
| 2004 | 14 | |
| 2003 | 9 | |
| 2002 | 9 | |
| 2001 | 6 | |
| 2000 | 8 | |
| 1999 | 8 | |
| 1998 | 6 | |
| 1997 | 7 | |
| 1996 | 6 | |
| 1995 | 6 | |
| 1994 | 2 | |
| 1993 | 3 | |
| 1991 | 6 | |
| 1990 | 3 | |
| 1989 | 1 | |
| 1988 | 2 | |
| 1987 | 2 | |
| 1964 | 1 |
Counts the 873 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Disease mechanisms
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Tau biomarkers
- Brain tissue and pathology
- Hippocampus size on brain scans